Product Highlight - Nustendi
14 Sep 2023
Add On to Take Back Control: A first-in-class oral, once-daily fixed-dose combination for additional LDL-C lowering1
- NUSTENDI® delivered a significant 38% reduction in LDL-C†2
- Well tolerated in clinical studies and limited musculoskeletal side effect1
- Can be taken with or without food1
†vs placebo on top of maximally tolerated statins.2
References:
1. NUSTENDI®. HK Prescribing Information Apr 2023.
2. Ballantyne CM et al. Eur J Prev Cardiol. 2020; 27(6): 593-603.
HK-DAI-NN-2307007; Date of Approval: Jul 2023
DAIICHI SANKYO HONG KONG LIMITED
Unit 1205, 12F, Sino Plaza, 255-257 Gloucester Rd, Causeway Bay
Tel: (+852) 2868 9072 • Fax: (+852) 2801 4341
https://www.daiichisankyo.com.hk/Enquiry
